Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation

Miaomiao Wen,1 Jinghua Xia,1 Ying Sun,1 Xuejiao Wang,1 Xianghui Fu,2 Yanning Zhang,1 Zhipei Zhang,1 Yongan Zhou,1 Xiaofei Li1 1Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi’an 710038, Shaanxi, China; 2Department of Clinical Immunology, Xijing H...

Full description

Bibliographic Details
Main Authors:	Wen M, Xia J, Sun Y, Wang X, Fu X, Zhang Y, Zhang Z, Zhou Y, Li X
Format:	Article
Language:	English
Published:	Dove Medical Press 2018-11-01
Series:	Biologics: Targets & Therapy
Subjects:	non-small cell lung cancer epidermal growth factor receptor-tyrosine kinase inhibitor chemotherapy adjuvant therapy retrospective study
Online Access:	https://www.dovepress.com/combination-of-egfr-tkis-with-chemotherapy-versus-chemotherapy-or-egfr-peer-reviewed-article-BTT

Similar Items

The role of EGFR‐TKIs as adjuvant therapy in EGFR mutation‐positive early‐stage NSCLC: A meta‐analysis
by: Chutong Lin, et al.
Published: (2021-04-01)

Efficacy of Chemotherapy after EGFR-TKIs Resistance in 191 Patients with Unknow EGFR Gene Mutation in Advanced Lung Adenocarcinoma
by: Ping HE, et al.
Published: (2013-10-01)

Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis
by: Chaoyu HONG, et al.
Published: (2016-12-01)

Research Progress on the Combination Therapy of EGFR-TKIs and Metformin  in Acquired Resistance to EGFR-TKIs in Non-small Cell Lung Cancer
by: Jiamin WANG, et al.
Published: (2023-11-01)

Detection and Evaluation of EGFR Mutation Status in Serum of Patients with Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs
by: Ling MA, et al.
Published: (2013-06-01)

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
by: Wen-Shuo Wu, et al.
Published: (2014-06-01)

Research Progress of New Generation EGFR-TKIs after Third-generation
by: Yuanyuan LIU, et al.
Published: (2020-11-01)

Chemotherapy outcomes in EGFR‐TKI resistant patients with common and uncommon EGFR mutation: An exploratory retrospective cohort study
by: Chien‐Yu Lin, et al.
Published: (2023-07-01)

Local Treatment Combined with EGFR-TKIs for Advanced Non-small Cell Lung Cancer with Solitary Progression during EGFR-TKI Treatment
by: Xin ZHANG, et al.
Published: (2013-10-01)

Successful Treatment of Combined Large Cell Neuroendocrine Carcinoma Harboring an EGFR Mutation with EGFR-TKIs plus Bevacizumab: A Case Report
by: Satoshi Muto, et al.
Published: (2020-11-01)

Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations
by: Fang Wang, et al.
Published: (2019-03-01)

Treatment with immune checkpoint inhibitors after EGFR‐TKIs in EGFR‐mutated lung cancer
by: Takashi Ito, et al.
Published: (2022-02-01)

Management of Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR-TKIs
by: Barbara eMelosky, et al.
Published: (2014-09-01)

Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR‐mutant non‐small cell lung cancer
by: Si‐Yu Lei, et al.
Published: (2023-08-01)

Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis
by: Limin CHEN, et al.
Published: (2019-05-01)

Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC
by: Sangtian Liu, et al.
Published: (2021-03-01)

Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis
by: Kang Qin, et al.
Published: (2020-04-01)

Efficacy of EGFR‐TKIs with or without upfront brain radiotherapy for EGFR‐mutant NSCLC patients with central nervous system metastases
by: Yu Saida, et al.
Published: (2019-11-01)

Investigating the Efficacy of EGFR-TKIs and Anti-VEGFR Combination in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
by: Prashant Sakharkar, et al.
Published: (2024-03-01)

Advances in Long Non-coding RNAs on Resistant to EGFR-TKIs  in Non-small Cell Lung Cancer
by: Shubin LI, et al.
Published: (2018-02-01)

Efficacy and resistance of EGFR-TKIs for first-line treatment for compound EGFR mutations positive non-small cell lung cancer
by: GUAN Xuhui, et al.
Published: (2022-12-01)

Role of GPER1 in the Mechanism of EGFR-TKIs Resistance in Lung Adenocarcinoma
by: Zhenhua Li, et al.
Published: (2022-05-01)

Concomitant Mutations in EGFR 19Del/L858R Mutation and Their Association with Response to EGFR-TKIs in NSCLC Patients
by: Liang H, et al.
Published: (2020-09-01)

Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in <i>EGFR</i>-Mutant Stage III-pN2 Lung Adenocarcinoma
by: Qiwen Li, et al.
Published: (2021-04-01)

Comprehensive Comparison Between Adjuvant Targeted Therapy and Chemotherapy for EGFR-Mutant NSCLC Patients: A Cost-Effectiveness Analysis
by: Wenqian Li, et al.
Published: (2021-03-01)

Analyzing the Sensitivity of EGFR-L861Q Mutation to TKIs and A Case Report
by: Xingxing WANG, et al.
Published: (2015-09-01)

Curative Effect of EGFR-TKIs with Anti-angiogenic Drugs as the Treatment for Patients with Advanced EGFR-mutant Non-small Cell Lung Cancer：a Meta-analysis
by: LI Yong, LONG Yong, ZHAO Chong, ZHANG Guanqing, SU Yanhe
Published: (2022-03-01)

Primary Application of Radiofrequency Ablation after Locally Progression of EGFR-TKIs in Non-small Cell Lung Cancer
by: Baodong LIU, et al.
Published: (2016-12-01)

Assessing EGFR‐mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy
by: Wei‐Chun Chen, et al.
Published: (2024-04-01)

Consumption and cost trends of EGFR TKIs: influences of reimbursement and national price negotiation
by: Di Wu, et al.
Published: (2022-04-01)

Clinical Predictive Factors associated with First Line EGFR-TKI Efficacy  in Advanced NSCLC Patients with EGFR Mutations
by: Minjiang CHEN, et al.
Published: (2019-02-01)

A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation
by: K. K. Laktionov, et al.
Published: (2019-06-01)

Radiotherapy with continued EGFR‐TKIs for oligoprogressive disease in EGFR‐mutated non‐small cell lung cancer: A real‐world study
by: Chunhong Hu, et al.
Published: (2023-01-01)

An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer
by: Yuexiao Qi, et al.
Published: (2022-08-01)

Effect of β-Blocker in Treatment-Naïve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs
by: Chia-Hao Chang, et al.
Published: (2020-10-01)

Efficacy Differences of First-line EGFR-TKIs Alone vs in Combination with Chemotherapy in Advanced Lung Adenocarcinoma Patients with Sensitive EGFR Mutation and Concomitant Non-EGFR Genetic Alterations
by: Guowei ZHANG, et al.
Published: (2022-09-01)

The efficacy of immune checkpoint inhibitors in advanced EGFR-Mutated non-small cell lung cancer after resistance to EGFR-TKIs: Real-World evidence from a multicenter retrospective study
by: Jia Hu, et al.
Published: (2022-09-01)

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
by: Chieh-Lung Chen, et al.
Published: (2023-09-01)

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review
by: Yijia Guo, et al.
Published: (2020-12-01)

Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated NSCLC patients who develop brain metastasis
by: Wenxian Wang, et al.
Published: (2018-10-01)